Hasn't Cell Therapeutics Ever Heard of All-Nighters?

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

Talk about gaming the system.

Cell Therapeutics' (Nasdaq: CTIC  ) second chance in front of the Food and Drug Administration came via an unusual path. Instead of running a new clinical trial, the biotech went over the reviewers' heads, appealing the decision, which eventually led to the company's belief that the data would be reconsidered.

After resubmitting, the FDA scheduled an advisory committee, which I said was a sign that things weren't going to be straightforward.

Who knew how right I'd be?

Cell Therapeutics said earlier today that it was voluntarily withdrawing its application for pixantrone because it didn't have enough time to prepare for the advisory panel meeting on Feb. 9. The company wasn't very forthcoming about what it needed to prepare for the meeting, but I guess it's more work than can be accomplished with a few all-nighters preparing for the big test.

By withdrawing the application, the advisory panel meeting is cancelled, and Cell Therapeutics can get it rescheduled after resubmitting its application later in the year. I'll bet there are a few college students who wished finals worked that way.

Maybe the company was acting like a college student and procrastinating because it was doing something more fun. Cell Therapeutics apparently had enough time to finalize plans on what it'll call the drug if it ever makes it to market: Pixuvri. It's certainly more fun to daydream about treating non-Hodgkin's lymphoma patients, even if it is as a last line of defense after treatment with drugs such as Spectrum Pharmaceuticals' (Nasdaq: SPPI  ) Zevalin and  Roche (OTC: RHHBY) and Biogen Idec's (Nasdaq: BIIB  ) Rituxan get a crack at them.

The move will likely delay Pixuvri's approval beyond the April 24 decision date, figure on a decision six months after the company resubmits. Whether it's a sign that Pixuvri is less likely to be approved is hard to say. Cell Therapeutics said the decision was made after communications with the FDA, so clearly an approval isn't as straightforward as the biotech was hoping for. On the other hand, perhaps the FDA gave the company a cheat sheet and the delay will help Cell Therapeutics be prepared for exactly what the advisory committee members want.

The perma-bulls can only hope the company doesn't drop out or end up in reform school.

If you are looking for outsized returns from little-known health-care companies, Motley Fool co-founder David Gardner has uncovered a small medical-device stock we're so confident in, we are offering you a chance to Discover the Next Rule-Breaking Multibagger in our new special report. It's available for a limited time only, so download your copy for free today!

Fool contributor Brian Orelli holds no position in any company mentioned. Click here to see his holdings and a short bio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Read/Post Comments (2) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On January 30, 2012, at 8:47 PM, mt48 wrote:

    You are pretty close when you made this statement!

    On the other hand, perhaps the FDA gave the company a cheat sheet and the delay will help Cell Therapeutics be prepared for exactly what the advisory committee members want.

    Yes you are, but not close enough!

  • Report this Comment On January 31, 2012, at 3:37 PM, Quaker08 wrote:

    If you invested $200,000 in CTIC circa 2002, you would now have roughly $1 to show for it. Be extremely careful with this company. Management has been a serial destroyer of shareholder wealth. The next reverse split should be just around the corner.

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1768970, ~/Articles/ArticleHandler.aspx, 10/24/2016 8:26:35 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 2 days ago Sponsored by:
DOW 18,145.71 -16.64 -0.09%
S&P 500 2,141.16 -0.18 -0.01%
NASD 5,257.40 0.00 0.00%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/21/2016 4:00 PM
CTIC $0.40 Down +0.00 +0.00%
CTI BioPharma CAPS Rating: **
BIIB $290.65 Down +0.00 +0.00%
Biogen CAPS Rating: *****
SPPI $3.94 Down +0.00 +0.00%
Spectrum Pharmaceu… CAPS Rating: ***